Affordable Preeclampsia Therapeutics.

Preeclampsia is one of the leading causes of maternal and perinatal morbidity and mortality, particularly in resource-limited settings. Treatment options for this devastating condition remain extremely limited. The successful application of RNAi technology to suppress the pathogenic protein soluble FMS-like tyrosine kinase-1 (sFLT1) in a baboon model of preeclampsia portends the development of effective therapies potentially accessible to areas with the greatest burden of disease.